Get started
Author

Purnima Shakya

Observed name: Shakya, P. B.
Institution: Mayo Clinic
OpenAlex ID: A5004517274
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
2024 · Amin H. Nassar, Ritujith Jayakrishnan, et al. · Journal of Thoracic Oncology · 18
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
2024 · Ritujith Jayakrishnan, Amin Nassar, et al. · Journal of Clinical Oncology · 5
PDF
Effectiveness of tocilizumab in obese patient for treatment of severe COVID-19 pneumonian
2022 · Oshna Pandey, Samish Adhikari, et al. · Figshare · 1
A Tobit Analysis of the Adoption and Use Rates of Fertilizer on Wheat in the Eastern Tarai of Nepal
1985 · Flinn, J. C., Shakya, P. B., et al. · RePEc: Research Papers in Economics · 1
Peer Review Report For: Case Report: Effectiveness of tocilizumab in obese patient for treatment of severe COVID-19 pneumonia [version 1; peer review: 1 approved with reservations]
2023 · Oshna Pandey, Samish Adhikari, et al.
PDF
Case Report: Effectiveness of tocilizumab in obese patient for treatment of severe COVID-19 pneumonia
2022 · Oshna Pandey, Samish Adhikari, et al. · F1000Research
WASH and food security in Surkhet District, Nepal.
2013 · Giri R. Khatri, Purnima Shakya · Urban Agriculture Magazine
Works count: 7
Citation count: 25
H-index: 2
I10-index: 1
Year
Topic
Type